The 130-year old healthcare conglomerate sells everything from baby shampoo to surgical staples and cancer drugs (it also divested itself of Splenda, the artificial sweetener.) That diversification helped buoy giant J&J in 2015; the company’s strong pharmaceutical sales made up for the less impressive performances of its consumer and medical device divisions. The company’s revenues grew 2.6% in the US, but slid 5.7% worldwide in 2015, largely due to currency fluctuations and the sharp decline in sales of its Hepatitis C drug, Olysio.
News about Johnson & Johnson
Lower prices could be on the horizon.
Including Disney's Bob Iger and GM's Mary Barra
But Dupixent's high cost could be a problem.
The industry is wary of the coming FDA streamlining.
Videos about Johnson & Johnson
Group Worldwide Chairman Sandi Peterson explains
Group worldwide chairman Sandi Peterson explains
According to this Johnson & Johnson exec